Fortress Biotech, Inc. (NASDAQ:FBIOP – Get Free Report) was the recipient of a significant increase in short interest in the month of September. As of September 30th, there was short interest totaling 1,600 shares. Based on an average daily trading volume, of 20,345 shares, the days-to-cover ratio is currently 0.1 days.
Fortress Biotech Stock Performance
Shares of NASDAQ:FBIOP traded down $0.08 during trading on Friday, reaching $16.81. 3,799 shares of the company were exchanged, compared to its average volume of 19,530. The business’s fifty day simple moving average is $18.04 and its 200-day simple moving average is $17.55. Fortress Biotech has a 12-month low of $6.27 and a 12-month high of $21.43.
Fortress Biotech Company Profile
Fortress Biotech, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious and underserved diseases. Its research and development activities span oncology, immunology, infectious diseases, rare diseases and dermatology, with programs developed internally and through a network of subsidiary companies and strategic partners.
The company’s portfolio has included biologic therapies, small-molecule medicines and gene therapies. Fortress has supported the development of products such as cosibelimab, an investigational monoclonal antibody targeting PD-L1, as well as dermatology treatments developed through its Journey Medical subsidiary.
Featured Articles
- Five stocks we like better than Fortress Biotech
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
- Palantir’s Potential Next Catalyst After Retail Profit-Taking
- Morgan Stanley Beats on Earnings, But Shares Fall on Trading Mix
- RTX Locks In a Decade of Defense Dominance
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
